Stay updated on FG-3019 Combination in Pancreatic Cancer Clinical Trial

Sign up to get notified when there's something new on the FG-3019 Combination in Pancreatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FG-3019 Combination in Pancreatic Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:45:16.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update in the efficacy or pharmacokinetics evaluation of FG-3019 in combination with gemcitabine and erlotinib for subjects with locally advanced or metastatic pancreatic cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:53.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying inclusion and exclusion criteria for the study. Previously, it only mentioned that no information was provided about collaborators.
    Difference
    30%
    Check dated 2024-05-22T21:12:51.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T21:58:54.000Z thumbnail image

Stay in the know with updates to FG-3019 Combination in Pancreatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FG-3019 Combination in Pancreatic Cancer Clinical Trial page.